Saccharomyces boulardii

A live yeast culture — not a bacterium — measured in CFU

All articles checked for accuracy against the GB NHC Register and all sources have citations with verified links to their relevant studies.

Saccharomyces boulardii is a live yeast culture — not a bacterium — commonly listed by CFU rather than weight. That single distinction changes how it behaves and how it should be described on a label.

This piece explains what S. boulardii is, where it comes from, what CFU means for live cultures, and how to read the research without overstating effects. It also summarises safety considerations and WellsparQ’s labelling approach.

Ingredient Snapshot

What it is

A live yeast culture (a single-celled fungal organism) measured in CFU.

Where from

A strain of Saccharomyces cerevisiae, isolated from lychee and mangosteen skins.

Known for

A well-studied live yeast distinct from bacterial cultures, used as a characterised supplement strain.

Nearly every "friendly culture" on the shelf is a bacterium — a Lactobacillus, a Bifidobacterium, a strain with a name that sounds like a bacterium. Saccharomyces boulardii is the odd one out. It is a yeast: a living single-celled fungus, closely related to baker's and brewer's yeast. That single fact is the most important thing to understand about it, and it shapes everything from how it behaves to how it must be described. This piece explains what it is, where it came from, what "CFU" means, and how honestly to read its research.

A yeast, not a bacterium

S. boulardii is a strain of Saccharomyces cerevisiae — the same species as the yeast used to raise bread and ferment beer — selected and characterised as a distinct culture for supplement use ^¹. Because it is a fungus rather than a bacterium, it differs from the usual cultures in ways that are more than trivia: as a yeast it is naturally unaffected by antibacterial antibiotics, and it grows best at human body temperature ^¹.

The practical point for WellsparQ copy is one of accuracy. This ingredient is a live yeast, or a live culture — it is not a "live bacterial culture", and it must never be described as one. Precision here is part of getting the label right.

Where it came from

The strain has an origin story worth telling as history. In the 1920s, the French microbiologist Henri Boulard was in Indochina during an outbreak of cholera. According to the account, he observed local people brewing a calming tea from the skins of tropical fruit — lychee and mangosteen — and isolated from it the yeast that now bears his name: boulardii ^¹. The strain has been produced and studied commercially ever since, most familiarly as the characterised strain S. boulardii CNCM I-745 ^¹².

What "CFU" means

Live cultures are not measured by weight but by how many living cells they contain, expressed as colony-forming units (CFU) — literally the number of viable cells able to grow into a visible colony under laboratory conditions. A declaration of "5 billion CFU" is therefore a count of live organisms, guaranteed to a stated point (typically to end of shelf life for a well-specified product), not a milligram figure ^¹.

The research base, read honestly

S. boulardii has been studied more than most single cultures, mostly in the setting of diarrhoea. The honest summary is that there is a real, sizeable literature with genuinely mixed and often modest conclusions.

• A systematic review and meta-analysis in adults gathered randomised trials across several conditions and found the strongest supporting evidence in the prevention of antibiotic-associated diarrhoea and in acute diarrhoea, while noting variation in trial quality ^².
• A later analysis focused on antibiotic-associated dysbiosis likewise identified S. boulardii CNCM I-745 among the better-studied options, again within the limits of the available trials ^³.
• The Cochrane systematic review of probiotics for acute infectious diarrhoea is an important corrective: after including large, well-conducted trials, its authors concluded that any benefit on the duration of illness was uncertain and probably small — a reminder that bigger, better trials often shrink earlier signals ^⁴.

So the picture is neither empty nor settled. There is a substantial research base, some of it supportive, some of it cautionary, much of it heterogeneous. As makes clear, none of it may appear as a WellsparQ benefit — and the very word "probiotic" is itself treated in the EU/UK as an unauthorised implied health claim, so it is avoided in consumer copy.

Safety — a section that must be included

For most healthy adults S. boulardii is well tolerated. But because it is a live organism, there is one specific, well-documented risk that a responsible brand must flag.

• In vulnerable patients — the critically ill, the immunocompromised, and especially those with a central venous catheter (central line) — the yeast has, rarely, entered the bloodstream and caused fungaemia (a Saccharomyces bloodstream infection). This is documented in a systematic review of the epidemiology of Saccharomyces fungaemia ^⁵ and in a study specifically linking cases to administration of S. boulardii-containing products, including transmission via handling near central lines ^⁶.
• For this reason, S. boulardii should not be used by critically ill or severely immunocompromised people, or those with a central line, except under medical supervision ^⁵⁶.
• Anyone who is pregnant or breastfeeding, or who has a serious underlying illness, should speak to a GP or pharmacist before use.

This is not a reason to avoid the ingredient in healthy adults, but it is a reason to carry the warning plainly.

How WellsparQ uses it

Source: WellsparQ Supplements Database. The declaration is a live-cell count (CFU), not a weight — the correct way to specify a living culture. The organism itself is not animal-derived and the ingredient is suitable for vegetarians; its vegan status should be confirmed against the finished formula and its excipients (some yeast capsules use lactose or other carriers) rather than assumed.